Oral,
Direct Factor Xa Inhibitors and Thromboembolic Disorders
Please
read through the following information and click continue.
ACPE Universal Program Number:
207-000-09-002-H01-P
Release
Date: February 1, 2009
Expiration Date: February 1, 2012
Statement
of Need
Arterial
and venous thromboses are major causes of morbidity and mortality.
Arterial thrombosis is the most common cause of myocardial infarction,
ischemic stroke and limb gangrene. Venous thrombosis, such as deep vein
thrombosis (DVT), may lead to pulmonary embolism (PE), which can be
fatal. Anticoagulants are the foundation for prevention and treatment
of venous and arterial thromboembolic diseases. Heparins and vitamin K
antagonists were discovered more than 60 years ago and have proven
effectiveness. By educating themselves about the various conditions and
treatment options, pharmacists can better assist their patients.
Learning
Objectives
Upon
successful completion of this activity, the pharmacist should be able
to:
- List the advantages and disadvantages of currently available anticoagulants.
- Discuss the role of Factor Xa (FXa) in the coagulation cascade and the rationale for selected FXa inhibition as a target for drug development.
- Discuss the pharmacology of apixaban and rivaroxaban: mechanism of action, pharmacokinetics and pharmacodynamics.
- Discuss the clinical data with rivaroxaban.
- Discuss the clinical data with apixaban.
Target
Audience
The
target market for this activity is pharmacists.
Instructions
for Participation
To
receive a certificate of completion that indicates your eligibility for
continuing education credit, you must:
- Review the content of the activity.
- Successfully complete the post-test (70% or higher).
- You will have two (2) opportunities to successfully complete the activity.
Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.
Fee
There
is no fee for this activity.
Accreditation
Pharmacists
NCPA is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education.
This program will provide 2 contact hours (.20 CEUs) of continuing
pharmacy education credit under the number 207-000-09-002-H01-P.
Faculty
Karissa
Y. Kim, PharmD, CACP, BCPS, is a clinical assistant
professor
of pharmacy practice at the University of Cincinnati Winkle College of
Pharmacy, and is also a clinical ambulatory care pharmacist.
Bradley E. Hein, PharmD, is a clinical assistant professor of pharmacy practice at the University of Cincinnati Winkle College of Pharmacy and is a clinical internal medicine pharmacist at the Christ Hospital in Cincinnati.
Patricia R. Wigle, PharmD, BCPS, is clinical associate professor of pharmacy practice at the University of Cincinnati Winkle College of Pharmacy, and is a clinical pharmacist in family medicine.
Disclosure
Declaration
It
is the policy of the National Community Pharmacists Association (NCPA)
to ensure independence, balance, objectivity, scientific rigor, and
integrity in all of their continuing education activities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.
Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
Software Requirements
|
PC *Required to view Printable PDF Version |
MAC |